摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-(2-chloromethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one | 938460-74-3

中文名称
——
中文别名
——
英文名称
(S)-(2-chloromethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
英文别名
(S)-2-(Chloromethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one;(7S)-2-(chloromethyl)-1'-(2-trimethylsilylethoxymethyl)spiro[6,8-dihydrocyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridine]-2'-one
(S)-(2-chloromethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one化学式
CAS
938460-74-3
化学式
C25H28ClN3O2Si
mdl
——
分子量
466.055
InChiKey
MVPRXKIBRCTSKN-VWLOTQADSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.06
  • 重原子数:
    32
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.4
  • 拓扑面积:
    55.3
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为产物:
    描述:
    (S)-(2-hydroxymethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one 在 氯化亚砜 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 生成 (S)-(2-chloromethyl)-1'-{[2-(trimethylsilyl)ethoxy]methyl}-6,8-dihydrospiro[cyclopenta[g]quinoline-7,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one
    参考文献:
    名称:
    [EN] CGRP RECEPTOR ANTAGONISTS
    [FR] ANTAGONISTES DE RÉCEPTEURS DE CGRP
    摘要:
    公式(I)的化合物(其中变量A1、A2、A3、环B、m、n、J、E1、E2、E3、R5、RPG和Y如本文所述),这些化合物可用作CGRP受体的拮抗剂,并可用于治疗或预防涉及CGRP受体的疾病,如头痛,特别是偏头痛和群集性头痛。该发明还涉及包含公式(I)化合物的制药组合物以及在涉及CGRP受体的疾病的预防或治疗中使用这些化合物和组合物的用途。
    公开号:
    WO2010107605A1
点击查看最新优质反应信息

文献信息

  • Spirolactam aryl cgrp receptor antagonists
    申请人:Bell Ian M.
    公开号:US20090247514A1
    公开(公告)日:2009-10-01
    Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , E 1 , E 2 , E 3 , E 4 , E 5 , G 1 , G 2 , J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    化学式为I的化合物:(其中变量A1、A2、A3、A4、A5、A6、A7、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述)是CGRP受体拮抗剂,可用于治疗或预防CGRP参与的疾病,如偏头痛。本发明还涉及包含这些化合物的制药组合物以及使用这些化合物和组合物预防或治疗CGRP参与的疾病的方法。
  • Spirolactam aryl CGRP receptor antagonists
    申请人:Merck Sharp & Dohme Corp.
    公开号:US07851464B2
    公开(公告)日:2010-12-14
    Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, E1, E2, E3, E4, E5, G1, G2, J and K are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    化合物I的化学式为:(其中变量A1、A2、A3、A4、A5、A6、A7、E1、E2、E3、E4、E5、G1、G2、J和K如本文所述),这些化合物是CGRP受体拮抗剂,可用于治疗或预防CGRP参与的疾病,如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。
  • CGRP RECEPTOR ANTAGONISTS
    申请人:Stump Craig A.
    公开号:US20120010193A1
    公开(公告)日:2012-01-12
    Compounds of Formula (I) (wherein variables A 1 , A 2 , A 3 , ring-B, m, n, J, E 1 , E 2 , E 3 , R 5 , RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.
    公式(I)的化合物(其中变量A1,A2,A3,环B,m,n,J,E1,E2,E3,R5,RPG和Y如本文所述),其作为CGRP受体拮抗剂有用,并且在治疗或预防涉及CGRP受体的疾病方面有用,例如头痛,特别是偏头痛和集群头痛。本发明还涉及包含公式(I)化合物的制药组合物以及在预防或治疗涉及CGRP受体的疾病方面使用这些化合物和组合物。
  • CGRP receptor antagonists
    申请人:Stump Craig A.
    公开号:US08778957B2
    公开(公告)日:2014-07-15
    Compounds of Formula (I) (wherein variables A1, A2, A3, ring-B, m, n, J, E1, E2, E3, R5, RPG and Y are as described herein), which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising the compounds of formula (I) and the use of these compounds and compositions in the prevention or treatment of diseases in which CGRP receptors are involved.
    式(I)的化合物(其中变量A1,A2,A3,环B,m,n,J,E1,E2,E3,R5,RPG和Y如本文所述),它们可用作CGRP受体拮抗剂,并且可用于治疗或预防涉及CGRP受体的疾病,例如头痛,特别是偏头痛和群集性头痛。本发明还涉及包含式(I)的化合物的制药组合物,以及在预防或治疗涉及CGRP受体的疾病中使用这些化合物和组合物的用途。
  • WO2007/61692
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多